Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention

NCT04273061 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT04273061
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04273061 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Canadian Atezolizumab Precision Targeting for Immunotherapy Intervention
Lead sponsor
British Columbia Cancer Agency
Phase
Phase 2
Overall status
Recruiting
Start date
June 17, 2020
Completion date
October 31, 2027
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, gastrointestinal cancer, genitourinary cancer, gynecologic cancer, head and neck cancer, lung cancer, sarcoma, skin cancer, unknown primary tumors